This upregulation and reprogramming of glucose metabolism induced by LIF overexpression were observed in different subtypes of breast cancers, including luminal A, basal-like, Her2+, and TNBC cancers, in both in vitro cultured cells and in vivo xenograft tumor models. The gene discussed is ERBB2; the disease is cancer.